Metaraminol bitartrate impurity, synthetic method and application

The synthesis method of the impurity (S)-N-benzyloxycarbonyl-5,5-bis(4-benzyloxyphenyl)-4-methyloxazolidin produced in the synthesis of interhydroxylamine of heavy tartaric acid was solved The problem of not including impurities in the prior art provides a new method for quality control of inter-hydroxylamine of heavy tartaric acid, which improves the safety of drugs.

CN119080710AInactive Publication Date: 2024-12-06SHANGHAI MODERN HASEN SHANGQIU PHARMA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411062642.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The impurities (S)-N-benzyloxycarbonyl-5,5-bis(4-benzyloxyphenyl)-4-methyloxazolidin produced during the synthesis of interhydroxylamine of heavy tartaric acid are not included in the pharmacopoeia. Affects drug quality control.

Method used

(S)-N-benz-L-alanine and paraformaldehyde were performed in a solvent to produce (S)-N-benz-yloxycarbonyl-4-methyl-5-oxooxazolidin and with 3-benzyl Oxygen halobenzene is used to generate heavy tartaric acid interhydroxylamine impurities through Grignard reaction, providing its synthesis method and application for quality control.

Benefits of technology

The quality control of interhydroxylamine of heavy tartaric acid was achieved, and a new compound was provided as a reference product, which improved the safety and effectiveness of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention relates to a synthesis method of an m-hydroxylamine bitartrate impurity, which comprises the following steps: by taking N-Cbz-L-alanine as a raw material, reacting with paraformaldehyde to obtain (S)-N-carbobenzoxy-4-methyl-5-oxazolidine, then carrying out Grignard reaction on the (S)-N-carbobenzoxy-4-methyl-5-oxazolidine and 3-benzyloxybromobenzene to obtain the m-hydroxylamine bitartrate impurity (S)-N-carbobenzoxy-5, 5-oxazolidine, and finally carrying out reaction on the (S)-N-carbobenzoxy-4-methyl-5-oxazolidine and 3- the catalyst is 2, 5-bis (4-benzyloxyphenyl)-4-methyl oxazolidine. The impurity can be used for controlling the quality of the m-hydroxylamine heavy wine acid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of organic synthesis, and in particular relates to a meta-hydroxylamine ditartaric acid impurity, a synthesis method and an application thereof. Background Art

[0002] Metahydroxylamine bitartrate (1, structural formula shown below), chemical name (-)-α-(1-aminoethyl)-3-hydroxymethylbenzyl alcohol bitartrate, is an α-adrenaline receptor agonist, mainly acting on α receptors, suitable for the early treatment of shock, prevention and treatment of acute hypotension during spinal block anesthesia. It is clinically used for auxiliary symptomatic treatment of hypotension caused by bleeding, drug allergy, surgical complications, brain trauma or brain tumor combined with shock, and can also be used to treat hypotension caused by cardiogenic shock or sepsis.

[0003]

[0004] Meta-hydroxylamine bitartrate can be synthesized by the following route (CN107311875): N-Cbz-L-alanine is reacted with formaldehyde to obtain (S)-N-benzyloxycarbonyl-4-methyl-5-oxoxazolidine, which is then reacted with 3-benzyloxybromobenzene through a Grignard reaction to obtain (4S)-N-benzyloxycarbonyl-5-(3-(benzyloxy)phenyl)-5-hydroxy-4-methyloxazolidine, which is then reacted with sodium borohydride and catalytic hydrogenolysis to obtain meta-hydroxylamine, which is finally salified with tartaric acid to obtain meta-hydroxylamine bitartrate.

[0005]

[0006] It was found in the synthesis research that the above route will produce the impurity (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine during the synthesis process. This impurity is a byproduct of the Grignard reaction process and is currently not included in the pharmacopoeias of various countries. In order to better control the impurities in meta-hydroxylamine bitartrate and improve the safety and effectiveness of drugs, this application studies and provides a method for synthesizing this impurity. Summary of the invention

[0007] The purpose of this patent is to overcome the defects of the prior art and provide a new compound - the impurity (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine, and use it as a reference substance to control the quality of meta-hydroxylamine bitartrate.

[0008] The present invention also provides a synthesis method and application of the above-mentioned meta-hydroxylamine bitartrate impurity (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine.

[0009] To achieve the above object, the present invention adopts the following technical solution:

[0010] A meta-hydroxylamine bitartrate impurity, wherein the structural formula of the meta-hydroxylamine bitartrate impurity is as follows:

[0011]

[0012] A method for synthesizing meta-hydroxylamine bitartrate impurity, the synthesis route of which is as follows:

[0013]

[0014] The specific steps include:

[0015] 1) Cyclization reaction: In the presence of solvent 1, N-Cbz-L-alanine (compound 3) and polyformaldehyde are refluxed under the catalysis of p-toluenesulfonic acid to generate (S)-N-benzyloxycarbonyl-4-methyl-5-oxooxazolidine (compound 4);

[0016] 2) Grignard reaction: 3-Benzyloxyhalobenzene (Compound 5) is reacted with magnesium under iodine catalysis in solvent 2 under reflux to obtain 3-benzyloxyphenylmagnesium halide Grignard solution, which is then reacted with (S)-N-benzyloxycarbonyl-4-methyl-5-oxoxazolidine (Compound 4) to obtain the impurity (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine (Compound 2).

[0017] Specifically, in step 1), the molar ratio of N-Cbz-L-alanine to paraformaldehyde can be 1:1.3-1.5, preferably 1:1.4, and the paraformaldehyde is measured as formaldehyde. The molar ratio of N-Cbz-L-alanine to p-toluenesulfonic acid is 1:0.05-0.15, preferably 1:0.1.

[0018] Specifically, in step 1), the solvent 1 can be one or two of toluene, n-heptane, etc., preferably toluene, and the amount of solvent 1 is 4 to 6 times the mass of N-Cbz-L-alanine (W / W), preferably 4.5 times.

[0019] Furthermore, in step 1), the reflux reaction time is 5 to 7 hours.

[0020] Specifically, in step 2), the 3-benzyloxyhalobenzene may be 3-benzyloxychlorobenzene or 3-benzyloxybromobenzene, etc., preferably 3-benzyloxybromobenzene; the molar ratio of (S)-N-benzyloxycarbonyl-4-methyl-5-oxooxazolidine to 3-benzyloxyhalobenzene may be 1:2.2-2.6, preferably 1:2.4.

[0021] Specifically, in step 2), the molar ratio of (S)-N-benzyloxycarbonyl-4-methyl-5-oxoxazolidine to magnesium can be 1:2.3-2.7, preferably about 1:2.5; the weight ratio of (S)-N-benzyloxycarbonyl-4-methyl-5-oxoxazolidine to iodine can be 1:0.003-0.008, preferably about 1:0.005.

[0022] Further, in step 2), the second solvent is one or two of diethyl ether, tetrahydrofuran, etc., preferably tetrahydrofuran, and the amount of the second solvent is 10 to 18 times (V / W) of (S)-N-benzyloxycarbonyl-4-methyl-5-oxooxazolidine, preferably about 14 times.

[0023] Furthermore, in step 2), the reaction temperature for preparing the Grignard solution is the solvent reflux temperature, and the reflux reaction time for preparing the Grignard solution is 1 to 2 hours, preferably 1.5 hours; the Grignard reaction temperature is room temperature, and the reaction time is 2 to 4 hours, preferably 3 hours.

[0024] The invention provides application of the above-mentioned meta-hydroxylamine bitartrate impurity in quality control of meta-hydroxylamine bitartrate.

[0025] The present invention also provides a method for detecting the meta-hydroxylamine bitartrate impurity, which uses HPLC to detect the meta-hydroxylamine bitartrate impurity as a reference substance.

[0026] In the present invention, N-Cbz-L-alanine (3) and paraformaldehyde react in toluene under the catalysis of p-toluenesulfonic acid to generate (S)-N-benzyloxycarbonyl-4-methyl-5-oxoxazolidine (4), and 4 and 3-benzyloxyhalobenzene (5) are subjected to a Grignard reaction in a solvent to obtain (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine (2).

[0027]

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] The present invention adopts N-Cbz-L-alanine to react with polyformaldehyde to generate oxazolidine to protect the active hydrogen on the carboxyl group and the amino group, and then performs a Grignard reaction with 3-benzyloxybromobenzene to obtain the target product--the meta-hydroxylamine bitartrate impurity (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine. The meta-hydroxylamine bitartrate impurity is currently not included and reported in the pharmacopoeias and documents of various countries. The present invention discovers a new compound (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine, which can be used as a reference substance to detect the related impurities of meta-hydroxylamine bitartrate, so as to control the quality of meta-hydroxylamine bitartrate. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The present invention is the meta-hydroxylamine bitartrate impurity (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine 1 H spectrum; the inset in the figure is a local enlarged view;

[0031] Figure 2 The present invention is the meta-hydroxylamine bitartrate impurity (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine 13 C spectrum; the inset in the figure is a local enlarged view;

[0032] Figure 3 HPLC chromatogram of blank (mobile phase A) injection;

[0033] Figure 4 This is the HPLC chromatogram of the impurity control solution injection; in the figure, 12.9 minutes is the synthetic bitartrate hydroxylamine impurity;

[0034] Figure 5 It is the HPLC chromatogram of the test solution injection; in the figure, 9.28 minutes is meta-hydroxylamine bitartrate, and 12.9 minutes is the synthetic meta-hydroxylamine bitartrate impurity. DETAILED DESCRIPTION

[0035] The technical solution of the present invention is further described in detail below in conjunction with implementation examples, but the protection scope of the present invention is not limited thereto.

[0036] In the following examples, the raw materials used are all common commercial products that can be directly purchased in the art or can be prepared by conventional methods in the art.

[0037] Room temperature refers to 25±5°C.

[0038] Example 1 Preparation of (S)-N-benzyloxycarbonyl-4-methyl-5-oxooxazolidine (4)

[0039] Toluene 200 g, p-toluenesulfonic acid monohydrate 3.8 g (0.02 mol), N-Cbz-L-alanine (3) 44.6 g (0.20 mol), and paraformaldehyde 8.4 g (0.28 mol, based on a formaldehyde molecular weight of 30) were added to a reaction kettle, and the mixture was heated to reflux for water separation. The temperature during the water separation process gradually increased from 100° C. to about 112° C. After anhydrous water was separated, the mixture was refluxed for another 2 hours for water separation (a total of about 6 hours for water separation), and then cooled to room temperature. 200 ml of saturated aqueous sodium bicarbonate solution was added, stirred and separated, the organic layer was dried with 15 g of anhydrous sodium sulfate and about 80% of toluene was evaporated under reduced pressure, 100 g of n-heptane was added to the residue and stirred for 10 minutes, then cooled to 0-5°C, stirred for 1 hour and filtered, the filter cake was washed with n-heptane and dried at 50-60°C to obtain 43.3 g of white solid (S)-N-benzyloxycarbonyl-4-methyl-5-oxooxazolidine (4), with a yield of 92%.

[0040] Example 2 Preparation of (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine (2)

[0041] This reaction is an anhydrous and oxygen-free reaction. Before the reaction, the instrument must be fully dried and carried out under the protection of nitrogen or argon. A calcium oxide drying tube is added to the reaction to prevent water and carbon dioxide in the air from entering. 125 ml of tetrahydrofuran, 4.6 g of magnesium chips (0.19 mol, 2.53 eq), iodine (about 0.1 g) and 9.0 g of 3-benzyloxybromobenzene (5) are added to the reaction bottle, and stirring is started. After the reaction is initiated (the color of iodine disappears), a tetrahydrofuran solution of 3-benzyloxybromobenzene (composed of 38.4 g of 3-benzyloxybromobenzene and 75 ml of tetrahydrofuran, with a total of 47.4 g of 3-benzyloxybromobenzene (0.18 mol, 2.40 eq)) is added dropwise. The dropping speed is controlled to keep the reaction liquid slightly boiling. After the dropwise addition is completed, the reaction is refluxed in a water bath for 1.5 hours to make the magnesium chips almost disappear, and a Grignard solution of 3-benzyloxybromobenzene is obtained. The temperature was controlled below 5°C, and a solution consisting of 17.6 g (0.075 mol, 1.0 eq) of (S)-N-benzyloxycarbonyl-4-methyl-5-oxooxazolidine (4) and 50 ml of tetrahydrofuran was slowly added dropwise. After the addition, the mixture was stirred at room temperature for 3 hours. After the reaction was completed, tetrahydrofuran was evaporated under reduced pressure below 40°C, 300 ml of ethyl acetate was added, and 100 ml of 5.0 mol / L hydrochloric acid was added dropwise. After the addition, the temperature was raised to 50°C and stirred for 2 hours, then cooled to room temperature, the water layer was separated, and the organic layer was washed with water twice (300 ml each time), and then dried with 30 g of anhydrous sodium sulfate, and the ethyl acetate was evaporated under reduced pressure. 50 ml of anhydrous ethanol was added, and the mixture was concentrated under reduced pressure and evaporated to dryness to remove the residual ethyl acetate. 200 ml of anhydrous ethanol was added to the residue, and the mixture was heated under reflux to dissolve, and then the temperature was lowered to 0-5°C for recrystallization, filtered, and dried at 50-60°C to obtain 29.8 g of (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine (2), with a yield of 67.9%.

[0042] The obtained (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine 1 H spectrum data such as Figure 1 As shown, the details are as follows: 1 H NMR (Bruker, 400MHz, DMSO, δ): 7.42~7.44(4H,d), 7.17~7.38(15H,m), 7.07~7.11(1H,m), 7.04~ 7.08(1H,t),6.92(1H,s),6.84~6.86(1H,d),5.02~5.21(8H,m),4.59~4.61(1H,t),0.90(3H,d). 13 C data such as Figure 2 As shown, the details are as follows: 13 C NMR (Bruker, 100MHz, DMSO, δ): 158.59, 158.52, 158.01, 151.77, 151.70, 144.3 1,144.15,142.18,136.90,136.87,136.69,136.54,129.74,129.21,128.32,12 7.77,127.25,127.01,117.96,117.77,113.72,113.57,113.09,112.27,112.16,89.48,88.87,75.83,75.21,69.17,65.97,65.81,56.52,56.38,16.77,16.19.

[0043] Example 3 Detection of meta-hydroxylamine bitartrate impurities

[0044] High performance liquid chromatography (Chinese Pharmacopoeia 2020 Part IV General Rules 0512) was used for detection.

[0045] Chromatographic conditions: octadecylsilane bonded silica gel is used as filler (Welch Ultimate XB-C18 250×4.6mm, 5.0μm or chromatographic column with equivalent performance); 0.03% sodium hexane sulfonate solution (adjusted to pH 3.0±0.1 with 40% phosphoric acid solution)-acetonitrile (91:9, volume ratio) is used as mobile phase A; acetonitrile-0.03% sodium hexane sulfonate (adjusted to pH 3.0±0.1 with 40% phosphoric acid solution) (80:20, volume ratio) is used as mobile phase B, and the elution gradient is performed according to the table below; the column temperature is 35°C; the flow rate is 1.0 ml per minute; the detection wavelength is 220nm; the injection volume is 20μ1.

[0046] Table 1 Gradient elution program

[0047]

[0048] Test solution: Take meta-hydroxylamine bitartrate and add an appropriate amount of mobile phase A to dissolve it to make a 1.0 mg / ml solution.

[0049] Impurity control solution: Take an appropriate amount of the impurity and dissolve it in mobile phase A to make a 0.001 mg / ml solution.

[0050] Detection method: Take mobile phase A as blank, take impurity control solution and test solution and inject them according to the above chromatographic conditions, and record the HPLC chromatogram.

[0051] Chromatogram see Figure 3 , 4 , 5. It can be seen from the figure that: 9.28 minutes is bitartrate meta-hydroxylamine, 12.9 minutes is the synthetic bitartrate meta-hydroxylamine impurity (S)-N-benzyloxycarbonyl-5,5-di(4-benzyloxyphenyl)-4-methyloxazolidine, the impurity content is calculated by the peak area using the external standard method, and the impurity content is calculated according to the following formula.

[0052]

[0053] Depend on Figures 3 to 5 The results show that the content of meta-hydroxylamine bitartrate impurity in the test sample is 0.079%.

Claims

1. A meta-hydroxylamine bitartrate impurity, It is characterized in that The structural formula of the meta-hydroxylamine bitartrate impurity is as follows: 。 2. The method for synthesizing the meta-hydroxylamine bitartrate impurity according to claim 1, It is characterized in that The specific steps include: 1) Cyclic reaction: In the presence of solvent 1, compound 3 N - Cb - L Alanine and paraformaldehyde were refluxed under the catalysis of p-toluenesulfonic acid to generate compound 4 ( S )- N -benzyloxycarbonyl-4-methyl-5-oxoxazolidine; 2) Grignard reaction: Compound 5 3-benzyloxyhalobenzene is refluxed with magnesium in solvent 2 under iodine catalysis to obtain halogenated 3-benzyloxyphenylmagnesium Grignard solution, which is then reacted with compound 4 ( S )- N -Benzyloxycarbonyl-4-methyl-5-oxooxazolidine is obtained by Grignard reaction.

3. The method for synthesizing the meta-hydroxylamine bitartrate impurity as claimed in claim 2, It is characterized in that In step 1), N - Cb - L -The molar ratio of alanine to paraformaldehyde is 1:1.3~1.5; N - Cb - L -The molar ratio of alanine to p-toluenesulfonic acid is 1:0.05~0.

15.

4. The method for synthesizing the meta-hydroxylamine bitartrate impurity according to claim 2, It is characterized in that In step 1), the solvent 1 is one or both of toluene and n-heptane, and the amount of solvent 1 is N - Cb - L -4~6 times the mass of alanine.

5. The method for synthesizing the meta-hydroxylamine bitartrate impurity as claimed in claim 2, It is characterized in that In step 1), the reflux reaction time is 5 to 7 hours.

6. The method for synthesizing the meta-hydroxylamine bitartrate impurity as claimed in claim 2, It is characterized in that In step 2), the 3-benzyloxyhalobenzene is 3-benzyloxychlorobenzene or 3-benzyloxybromobenzene, ( S )- N The molar ratio of benzyloxycarbonyl-4-methyl-5-oxooxazolidine to 3-benzyloxyhalobenzene is 1:2.2-2.

6.

7. The method for synthesizing the meta-hydroxylamine bitartrate impurity as claimed in claim 2, It is characterized in that In step 2), ( S )- N -benzyloxycarbonyl-4-methyl-5-oxoxazolidine to magnesium molar ratio is 1:2.3~2.7; ( S )- N The weight ratio of benzyloxycarbonyl-4-methyl-5-oxooxazolidine to iodine is 1:0.003-0.

008.

8. The method for synthesizing the meta-hydroxylamine bitartrate impurity as claimed in claim 2, It is characterized in that In step 2), the second solvent is one or both of diethyl ether and tetrahydrofuran, and the amount of the second solvent is ( S )- N -benzyloxycarbonyl-4-methyl-5-oxooxazolidine; the reflux reaction time for the preparation of the Grignard solution is 1 to 2 hours; the Grignard reaction temperature is room temperature, and the reaction time is 2 to 4 hours.

9. Use of the meta-hydroxylamine bitartrate impurity according to claim 1 in quality control of meta-hydroxylamine bitartrate.

10. A method for detecting meta-hydroxylamine bitartrate impurities, It is characterized in that The test was performed by HPLC with meta-hydroxylamine bitartrate as the reference substance.

Citation Information

Patent Citations

  • Method for synthesizing metaraminol bitartrate

    CN107311875A

  • Synthesis method of metaraminol bitartrate

    CN115260043A